Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
May 25 2021 - 4:05PM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, starting first with inflammatory bowel
disease (IBD), today announced that Mark McKenna, President and
CEO, and Laurens Kruidenier, CSO, will present at the Jefferies
Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30am
ET.
A live and archived webcast of the virtual
presentation will be available via the Events section of the
Prometheus Biosciences website.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment and
diagnosis of immune-mediated diseases, starting first with IBD. The
Company’s precision medicine platform, Prometheus360, combines
proprietary bioinformatics discovery methods with one of the
world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets. Prometheus is
headquartered in San Diego, CA.
Contacts:Noel KurdiVP Investor Relations and
Communications(646) 241-4400nkurdi@prometheusbiosciences.com
Media contactJuniper PointAmy Conrad(858)
914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024